Group Manager, Product Marketing

Minnetonka, MN (On-site)

$145K/yr – $180K/yrSenior Level7+ years expFull time

Posted 6 weeks ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own the cardiothoracic cryoNB franchise strategy and team, aligning upstream market development with downstream launch, while building a capable org and cross-functional trusted leadership across R&D, Regulatory, and Clinical.

  • Own therapy roadmap and cross-functional execution, including voice-of-customer, market assessments, and KOL engagement.
  • Lead team growth and mentorship, delivering coachable plans, budgets, and training pathways.
  • Coordinate with commercial and clinical teams to drive messaging, campaigns, and evidence generation aligned with therapy objectives.

Job Description

Responsibilities

  • Lead the product marketing team in the development and execution of the cardiothoracic Cryo Nerve Block therapy strategy, including upstream market development and downstream commercialization plans.
  • Set priorities and manage day-to-day activities of the team to ensure strong performance and growth across the team.
  • Develop the team through coaching and mentorship, supporting each individual’s career aspirations and development goals.
  • Serve as a strong communicator and trusted leader, effectively guiding cross-functional teams and fostering collaboration across Clinical, R&D, Scientific Affairs, Regulatory, and Medical Education.
  • Lead and guide the team to develop and implement upstream initiatives to build therapy foundation, including market assessments, procedure development, and voice-of-customer activities.
  • Contribute to FTE plans and budget plans. Build a highly capable team through education, on-job experiences, and mentoring/development.
  • Drive downstream marketing efforts such as messaging, promotional campaigns, and launch execution in partnership with commercial teams.
  • Establish and maintain relationships with key opinion leaders (KOLs) and cascade internal insights to inform strategy and product development.
  • Support clinical team with trial and registry activities, ensuring alignment with therapy objectives and evidence generation strategies.
  • Represent the franchise at relevant society conferences and professional meetings to support therapy awareness and adoption.
AtriCure logo

AtriCure

4.7 Glassdoor

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 37 million people worldwide. Electrophysiologists, cardiothoracic and thoracic surgeons around the globe use AtriCure technologies for the treatment of Afib, reduction of Afib related complications and post-operative pain management. AtriCure’s Isolator® SynergyTM Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AFTM Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE®+ and cryoSPHERE MAXTM probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit AtriCure.com or follow us on X (formerly Twitter) @AtriCure.

Founded in 2000
Mason, Ohio, USA
1.3K employees (88 in marketing)
94% recommend to a friend
95% CEO approval

Traffic Signals

Monthly Visitors
18.2K
Monthly Google Ads Budget
$2.1K
Traffic Source Mix
Search
41.3%
Direct
44.7%
Referral
7.4%
Social
4.6%
Paid
1.9%

Headcount Trend

Current headcount: ~1.3K

Marketing Team

Marketing Team Size
65 (5% of company)
Marketing Roles Posted (Last 30 Days)
4

Funding

Total Funding
$207M
Last Raise
$6M
Grant, 4 months ago

Funding History

  • Dec 2025
    Grant • $6M
  • May 2020
    Post IPO Equity • $175M
  • Jun 2002
    Series Unknown • $21M

Recent News